SCHEMBL20189519

SCHEMBL20189519

COC(=O)c1ccc(CN2CC(=O)NC2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
HDAC6 Q9UBN7 3/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
GAA P10253 3/20 0.48
LOXL2 Q9Y4K0 1/20 0.47
SIRT1 Q96EB6 1/20 0.46
FAAH O00519 1/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP11B2 P19099 1/20 0.46
HDAC1 Q13547 1/20 0.46
CHKA P35790 1/20 0.45
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP4A11 Q02928 1/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31773 0.84 LOXL2 (0.52) RAB9ALMNAHDAC6LOXL2SMN1; SMN2
SCHEMBL5138385 0.83 HDAC6 (0.73) RAB9ANPC1LMNAHTTHDAC6
SCHEMBL31947 0.79 LMNA (0.44) LMNAGAAKMT2ASMN1; SMN2MEN1
SCHEMBL6101068 0.79 GAA (0.73) RAB9AHDAC6GAAKMT2ASMN1; SMN2
SCHEMBL5189032 0.79 HDAC6 (0.52) RAB9ANPC1LMNAHTTHDAC6
SCHEMBL2414084 0.78 POLB (0.56) RAB9ANPC1LMNAHTTHDAC6
SCHEMBL31289951 0.77 TUBB4A (0.53) RAB9ANPC1LMNAHTTHDAC6
SCHEMBL28757730 0.77 EPHX2 (0.47) HDAC6HDAC2HDAC8GAA
SCHEMBL9164640 0.75 EPHX2 (0.49) HDAC6HDAC2HDAC8GAAKMT2A
SCHEMBL3948981 0.74 RAB9A (0.50) RAB9ANPC1LMNAHTTHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
WO-2018098209-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT RAB9A 3969/4885NPC1 2179/4885LMNA 704/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT RAB9A 3969/4885NPC1 2179/4885LMNA 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.